Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

='External Link';s.eVar3=s.prop5;s.prop15='79490252';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.anadyspharma.com/">www.anadyspharma.com. A telephone replay with slides will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 75270153. The webcast and telephone replay will be available through December 31, 2009.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the expected timing for enrolling the next cohort in the ANA598 Phase II study and for receiving 12 week data from the 200 mg bid cohort and 4 and 12 week data from the 400 mg bid cohort; (ii) the prospects of ANA598 being able to contribute to long-term treatment outcome as measured by SVR and the hope that ANA598 will be established as the leading non-nucleoside in HCV, suitable for combination with current SOC as well as with other direct antivirals currently in development; (iii) the ability for patients to achieve EVR and SVR in the ANA598 Phase II study; and (iv) assessments of the safety and tolerability profile of ANA598 based on the interim 4 week analysis. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues or will continue to have favorable results as the Phase II trial progresses. In addition, Anadys' results may be affected by competition from other biotechno
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Boston Scientific Corporation (NYSE: ... 2014 Credit Suisse Annual Healthcare Conference on Tuesday, November ... Dan Brennan , executive vice president and chief ... beginning at approximately 8:00 a.m. PT followed by a ... of the presentation and question and answer session will ...
(Date:10/30/2014)... NEW YORK , Oct. 30, 2014  The ... United States is growing steadily, thanks to ... years, as a result of the economic downturn, retail ... was a year of opportunities, as the number of ... market researcher,s report, Retail Clinics Market Overview and ...
(Date:10/30/2014)... NOTTINGHAM, United Kingdom , Oct. 30, 2014 /PRNewswire/ ... Inc., (Nasdaq: CBRX ) and ... assist drug developers with improved efficiency during clinical development ... San Diego next week. This ... enabling technologies platform, which it launched earlier this month. ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... Findings Reinforce March of Dimes Message: Start Taking a ... 11 Women who take folic acid supplements for ... cut their risk of having a premature baby by ... online journal, PLOS Medicine.The study links pre-conceptional folate supplementation ...
... Announces Positive Top Line Results of its Clinical Study ... Mass., May 11 Logical Therapeutics, Inc (Logical), a ... treat diseases associated with inflammation, today announced that Peter ... has been elected to the Company,s Board of Directors. ...
Cached Medicine Technology:Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 3Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 4
(Date:10/31/2014)... Energy Textiles has recently added a ... is now available online, and Energy Textile is providing ... infrared-active athletic gear over compression gear. , The ... been signed for Under Armour to provide team gear ... years. In light of this decision, Energy Textiles contemplates ...
(Date:10/31/2014)... IL – New research suggests that insomnia is a ... and other unintentional fatal injuries. The results underscore the ... the National Healthy Sleep Awareness Project. , Results show ... a dose-dependent manner with the number of insomnia symptoms ... 2.8 times more likely to die from a fatal ...
(Date:10/31/2014)... New York (PRWEB) October 31, 2014 ... Mineola Eye in Garden City, Long Island and the ... to their medical staff, according to North Shore Eye ... is the Emeritus Acting Chairman of the Department of ... and successful practice in Garden City for more than ...
(Date:10/31/2014)... In an effort to expand services and improve efficiency ... will soon offer orthodontics at his Oral & Maxillofacial Surgery ... , To build upon the high degree of care and ... known for, Dr. Jamali is welcoming an orthodontist that is ... as UCLA, Stanford and UCSF. He added that the new ...
(Date:10/31/2014)... Radiology and EMR Integration , “Surveys ... diagnostic imaging centers but Connectivity is Opportunity,” says ... “Differentiation is critical in all businesses today and ... the intense competition and the downward pressure on ... from the competition by fully integrating with the ...
Breaking Medicine News(10 mins):Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2
... April 24 The following are,excerpts from an article ... issued by,the Republican National Committee:, Congressional Democrats are ... presidential candidates, saying that even if,their party controls the ... For some senators, the promises made by Sens. ...
... for,Biomedical Research (FBR) Board Chairman Dr. Michael E. DeBakey ... Congress can,bestow, on Wednesday., "The recipients of this ... few, but they are iconic -- they include Thomas ... Bush. "Today we gather to recognize,that Michael DeBakey,s name ...
... is hosting a,credentialed educational forum on Friday, May ... Road. The session offers three CEUs, and is,entitled ... is from,8-8:30am with the session itself from 8:30-11:30am ... Session participants will gain a more complete ...
... Home Safety Council(R) Applauds Enactment of Safety of Seniors ... Council, the only,national nonprofit organization solely dedicated to preventing,unintentional ... Act. The bill, signed into law by President Bush ... in three Americans age 65 and older,falls and about ...
... LIONVILLE, Pa., April 24 West Pharmaceutical,Services, Inc. (NYSE: ... 2008 first,quarter financial results before the market opens on ... call to discuss the results and business,expectations at 9:00 ... (888) 790-3758 or (210) 839-8398. The passcode is WST., ...
... and 39 percent of federal inmates,have medical problems, ... of state and federal prisoners who were HIV-positive decreased,3.1 ... a report by the,Justice Department,s Bureau of Justice Statistics ... inmates and 39 percent of federal,inmates reported a current ...
Cached Medicine News:Health News:RNC: Dems Hedge on Healthcare 2Health News:Michael E. DeBakey Receives Congressional Gold Medal 2Health News:President Signs Elder Falls Bill Into Law 2Health News:West to Host 2008 First Quarter Conference Call 2Health News:Number of HIV-Positive State and Federal Inmates Continues to Decline 2Health News:Number of HIV-Positive State and Federal Inmates Continues to Decline 3
... The Vitros 950 provides power ... needs of high volume testing ... up to 900 results per ... store and perform the full ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Architect ci8200 is a flexible solution for your evolving laboratory offering high productivity, one report and one operator interface for both chemistry and immunoassay testing....
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
Medicine Products: